LRRK2 anticorps (Glu519)

N° du produit ABIN1882108

Détail du produit anti-LRRK2 anticorps

Antigène: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Épitope: AA 504-536, Glu519

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp LRRK2 est non-conjugé

Application: Western Blotting (WB)

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. Purified Rabbit Polyclonal Antibody (Pab)

Immunogène: This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 504-536 amino acids from human PARK8(LRRK2).

Clone: RB7205

Information d'application

Indications d'application: WB: 1:1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 2 mg/mL

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.

Références pour anticorps anti-LRRK2 (ABIN1882108)

Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." dans: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).

Shen: "Protein kinases linked to the pathogenesis of Parkinson's disease." dans: Neuron, Vol. 44, Issue 4, pp. 575-7, (2004) (PubMed).

Wszolek, Pfeiffer, Tsuboi, Uitti, McComb, Stoessl, Strongosky, Zimprich, Müller-Myhsok, Farrer, Gasser, Calne, Dickson: "Autosomal dominant parkinsonism associated with variable synuclein and tau pathology." dans: Neurology, Vol. 62, Issue 9, pp. 1619-22, (2004) (PubMed).

Détails sur LRRK2

Antigène: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Autre désignation: PARK8 (LRRK2) (LRRK2 Produits)

Synonymes: anticorps LRRK2, anticorps AURA17, anticorps DARDARIN, anticorps PARK8, anticorps RIPK7, anticorps ROCO2, anticorps 4921513O20Rik, anticorps 9330188B09Rik, anticorps AW561911, anticorps D630001M17Rik, anticorps Gm927, anticorps cI-46, anticorps leucine-rich repeat kinase 2, anticorps leucine rich repeat kinase 2, anticorps lrrk2, anticorps LRRK2, anticorps Lrrk2

Sujet: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

Synonyms: LRRK2, PARK8, Leucine-rich repeat serine/threonine-protein kinase 2, Dardarin

NCBI Accession: NP_940980

UniProt: Q5S007

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development